​

Pulmonx (LUNG) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LUNG Stock Forecast

Pulmonx (LUNG) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $2.50, with a high of $2.50 and a low of $2.50. This represents a 52.44% increase from the last price of $1.64.

- $3 $6 $9 $12 $15 High: $2.5 Avg: $2.5 Low: $2.5 Last Closed Price: $1.64

LUNG Stock Rating

Pulmonx stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (44.44%), 4 Hold (44.44%), 1 Sell (11.11%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 4 4 Strong Sell Sell Hold Buy Strong Buy

LUNG Price Target Upside V Benchmarks

TypeNameUpside
StockPulmonx52.44%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks19.90%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$2.50$6.25
Last Closing Price$1.64$1.64$1.64
Upside/Downside-52.44%281.10%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-42--6
Sep, 25-42--6
Aug, 25-42--6
Jul, 25142--7
Jun, 25142--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 31, 2025Jason BednarPiper Sandler$2.50$3.15-20.63%52.44%
Oct 31, 2024Jason BednarPiper Sandler$10.00$6.7947.28%509.76%
Aug 01, 2024William PlovanicCanaccord Genuity$16.00$7.42115.63%875.61%
Jun 04, 2024Frank TakkinenLoop Capital Markets$12.00$7.0071.43%631.71%
Jan 06, 2023Morgan Stanley$9.50$7.8820.56%479.27%
Dec 12, 2022Wells Fargo$6.00$6.22-3.54%265.85%
Dec 12, 2022Citigroup$10.00$5.8870.07%509.76%
Jul 18, 2022Stifel Nicolaus$20.00$16.3722.17%1119.51%
Jul 15, 2022Morgan Stanley$19.00$16.2117.21%1058.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 31, 2025Piper SandlerOverweightNeutraldowngrade
Mar 10, 2025Morgan StanleyEqual-WeightEqual-Weightinitialise
Dec 11, 2024CitigroupBuyNeutraldowngrade
Oct 31, 2024Piper SandlerOverweightOverweighthold
Jun 04, 2024Lake StreetBuyinitialise
Apr 03, 2024Wells FargoBuyBuyhold
Feb 27, 2023Wells FargoEqual-WeightOverweightupgrade
Jan 06, 2023Morgan StanleyEqual-WeightEqual-Weighthold
Dec 12, 2022Wells FargoEqual-WeightEqual-Weighthold
Dec 12, 2022CitigroupBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.90$-1.35$-1.59$-1.60$-1.44----
Avg Forecast$-2.22$-1.35$-1.62$-1.65$-1.56$-1.60$-1.36$-1.18$-0.77
High Forecast$-2.17$-1.32$-1.59$-1.64$-1.54$-1.46$-1.18$-0.73$-0.75
Low Forecast$-2.27$-1.38$-1.64$-1.66$-1.57$-1.72$-1.66$-1.58$-0.78
Surprise %-59.46%--1.85%-3.03%-7.69%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$32.73M$48.42M$53.66M$68.67M$83.79M----
Avg Forecast$31.74M$49.00M$52.16M$67.64M$82.32M$97.72M$117.21M$142.30M$165.70M
High Forecast$32.27M$49.82M$52.76M$67.87M$82.48M$98.49M$118.86M$144.30M$168.02M
Low Forecast$31.21M$48.19M$51.44M$67.40M$82.16M$96.94M$115.42M$140.12M$163.16M
Surprise %3.12%-1.20%2.89%1.53%1.79%----

Net Income Forecast

$-90M $-77M $-64M $-51M $-38M $-25M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-32.23M$-48.66M$-58.92M$-60.84M$-56.39M----
Avg Forecast$-84.21M$-53.02M$-56.89M$-60.84M$-58.98M$-63.82M$-54.41M$-48.20M$-29.05M
High Forecast$-82.39M$-42.41M$-45.51M$-48.67M$-58.41M$-55.59M$-44.65M$-27.72M$-28.47M
Low Forecast$-86.03M$-63.62M$-68.26M$-73.01M$-59.56M$-65.31M$-62.90M$-60.00M$-29.58M
Surprise %-61.72%-8.22%3.58%--4.39%----

LUNG Forecast FAQ

Is Pulmonx stock a buy?

Pulmonx stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 4 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Pulmonx is a favorable investment for most analysts.

What is Pulmonx's price target?

Pulmonx's price target, set by 9 Wall Street analysts, averages $2.5 over the next 12 months. The price target range spans from $2.5 at the low end to $2.5 at the high end, suggesting a potential 52.44% change from the previous closing price of $1.64.

How does Pulmonx stock forecast compare to its benchmarks?

Pulmonx's stock forecast shows a 52.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (19.90%).

What is the breakdown of analyst ratings for Pulmonx over the past three months?

  • October 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Pulmonx’s EPS forecast?

Pulmonx's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.6, marking a 11.11% increase from the reported $-1.44 in 2024. Estimates for the following years are $-1.36 in 2026, $-1.18 in 2027, and $-0.77 in 2028.

What is Pulmonx’s revenue forecast?

Pulmonx's average annual revenue forecast for its fiscal year ending in December 2025 is $97.72M, reflecting a 16.63% increase from the reported $83.79M in 2024. The forecast for 2026 is $117.21M, followed by $142.3M for 2027, and $165.7M for 2028.

What is Pulmonx’s net income forecast?

Pulmonx's net income forecast for the fiscal year ending in December 2025 stands at $-63.824M, representing an 13.17% increase from the reported $-56.394M in 2024. Projections indicate $-54.409M in 2026, $-48.2M in 2027, and $-29.051M in 2028.